Comparing Medium-Term Clinical Outcomes following XEN® 45 and XEN® 63 Device Implantation

Purpose. To evaluate medium-term clinical outcomes with XEN (R) 45 or XEN (R) 63 Gel Stent (Allergan, Dublin, Ireland) for treatment of primary open angle glaucoma (POAG). Materials and Methods. Retrospective, descriptive, and observational study involving 40 patients implanted with a XEN (R) 45 Gel Stent and 34 implanted with a XEN (R) 63 Gel Stent who had undergone POAG surgery and had been followed up and controlled between 12 and 36 months. Results. IOP dropped from 18.02 +/- 5.23 mmHg preop to 13.81 +/- 1.88, 14.80 +/- 2.23, and 14.62 +/- 1.90 at 1, 2, and 3 years after surgery (p<0.001) consecutively with XEN (R) 45 and from 19.00 +/- 6.11 mmHg preop to 15.47 +/- 2.45, 14.66 +/- 2.45, and 15.46 +/- 2.48 at 1, 2, and 3 years after surgery (p<0.001) with XEN (R) 63. The number of drugs used by patients to treat their glaucoma decreased after undergoing surgery in both groups. Within the XEN (R) 45 group, mean changes at 1 year, 2 years, and 3 years amounted to 70%, 74.3%, and 37.5%, respectively, whereas within the XEN (R) 63 group, the mean reduction was 75%, 79.8%, and 71.9%. When comparing the outcomes for two groups, the differences did not prove to be statistically significant. More than 90% of the procedures included in the study (using either gel-stent device) were completed without any noteworthy complications. Conclusion. POAG surgical procedures with either XEN (R) 45 or XEN (R) 63 Gel Stent implantation could be a safe and effective treatment approach.